Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 64Neoplasm Metastasis 25Kidney Neoplasms 21Neoplasms 16Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Prostatic Neoplasms 10Lung Neoplasms 8Brain Neoplasms 8Melanoma 7Colorectal Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroendocrine Tumors 6Liver Neoplasms 6Glioblastoma 6Gastrointestinal Stromal Tumors 6Carcinoma, Hepatocellular 6Thyroid Neoplasms 5Thymoma 5Small Cell Lung Carcinoma 5Recurrence 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma 4Adenocarcinoma 4

Interventions

Paclitaxel 2Nivolumab 2Bevacizumab 2liposomal doxorubicin 1dostarlimab 1Sunitinib 1Radiotherapy 1Ipilimumab 1Gemcitabine 1Erlotinib Hydrochloride 1Doxorubicin 1Celecoxib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Clear Cell × Sunitinib × Clear all
NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Cathay General Hospital

Phase 2 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡